LONDON, March 1 (Reuters) – AstraZeneca has sold rights to a non-core drug to a unit of Kyowa Hakko Kirin for an upfront payment of $70 million, a day after getting $500 million for two ageing heart…
The post AstraZeneca sells drug for $70 mln as divestment drive continues appeared first on NASDAQ.